Abbott has also added new customization options to enhance user comfort and discretion. These include a “silent mode” feature for FreeStyle Libre 3 systems, allowing users to mute glucose alarms for up to six hours – a useful option during meetings, sleep, or other moments where audio alerts may be disruptive.
For the first time, a single app supports all of Abbott’s CGM sensors available in the US, including the FreeStyle Libre 2, which offers customizable glucose alarms but previously required manual scanning
Key Takeaways
·One app now compatible with FreeStyle Libre 2, 2 Plus, 3, and 3 Plus sensors.
·Real-time data streaming eliminates scanning for many users.
·A gradual alarm option has also been introduced to provide subtler, less jarring alerts for rising or falling glucose levels.
Abbott is betting big on smarter, simpler continuous glucose monitoring (CGM).
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
The Development Bank of Wales and London-based Parkwalk Advisors led an investment round of £5m, almost doubling Ceryx Medical's total investment to date.
The new AI Precision Medicine platform supports the company’s flagship product, EvoLiver, which received US FDA breakthrough device designation in April.
Eko hopes its new partnership with Boehringer Ingelheim to develop algorithms for accurately detecting heart murmurs in dogs will pave the way for more collaborations with medical and pharmaceutical companies to advance early detection in humans as well as animals.
The Development Bank of Wales and London-based Parkwalk Advisors led an investment round of £5m, almost doubling Ceryx Medical's total investment to date.
SS Innovations reported its first SSi Mantra 3 robotic cardiac surgery in South America as it prepares to file for US FDA de novo clearance and a CE mark. The firm aims to challenge Intuitive Surgical with a lower-cost, flexible system targeting US and European markets.
Innovative Healthcare is asking for a permanent injunction against Johnson & Johnson subsidiary Biosense Webster after winning a $442 million antitrust verdict. The injunction aims to prevent continued anticompetitive practices in the electrophysiology catheter market.
